Get the latest Science News and Discoveries
Testing for residual cancer cells before blood cell transplant therapy is important and practical, new study finds - EurekAlert
<p><strong>Patients with a type of high-risk blood cancer are likely to do better if no trace of the cancer is detectable before they receive donor blood cells. The finding in JAMA Oncology emphasizes the importance of testing for lingering cancer cells in the body after people receive apparently successful chemotherapy treatment. “The good news is this testing is doable,” said Christopher Hourigan, a Virginia Tech professor and director of the Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C.</strong></p>
None
Or read this on Eureka Alert